GlassScriptPhysician profile
Robert H Schingler
NPI 1821037615
$5,390.98
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $1,342 · 2021: $1,992 · 2022: $403.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $760.44 | 2019-2022 | |
| Pfizer INC. | $607.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $555.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $459.03 | 2019-2021 | |
| Novo Nordisk INC | $436.07 | 2019-2022 | |
| Abbvie INC. | $416.36 | 2020-2022 | |
| Mylan Specialty L.P. | $274.73 | 2019-2021 | |
| Allergan, INC. | $222.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $200.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.49 | 2019-2022 | |
| Astellas Pharma US INC | $180.32 | 2019 | |
| Merck Sharp & Dohme LLC | $150.89 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $150.48 | 2019-2021 | |
| Lilly USA, LLC | $146.93 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $137.66 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $100.32 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $71.58 | 2021 | |
| Eisai INC. | $60.13 | 2021 | |
| Daiichi Sankyo INC. | $42.51 | 2019-2021 | |
| Therapeuticsmd, INC. | $36.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.95 | 2022 | |
| Sanofi Pasteur INC. | $23.67 | 2019 | |
| Almatica Pharma LLC | $21.58 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.36 | 2020 | |
| Vifor Pharma, INC. | $21.16 | 2019 | |
| Advanced Respiratory, INC | $17.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.64 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schingler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.